Management of perimenopausal and menopausal symptoms.


Journal

BMJ (Clinical research ed.)
ISSN: 1756-1833
Titre abrégé: BMJ
Pays: England
ID NLM: 8900488

Informations de publication

Date de publication:
08 08 2023
Historique:
medline: 10 8 2023
pubmed: 9 8 2023
entrez: 8 8 2023
Statut: epublish

Résumé

Most women worldwide experience menopausal symptoms during the menopause transition or postmenopause. Vasomotor symptoms are most pronounced during the first four to seven years but can persist for more than a decade, and genitourinary symptoms tend to be progressive. Although the hallmark symptoms are hot flashes, night sweats, disrupted sleep, and genitourinary discomfort, other common symptoms and conditions are mood fluctuations, cognitive changes, low sexual desire, bone loss, increase in abdominal fat, and adverse changes in metabolic health. These symptoms and signs can occur in any combination or sequence, and the link to menopause may even be elusive. Estrogen based hormonal therapies are the most effective treatments for many of the symptoms and, in the absence of contraindications to treatment, have a generally favorable benefit:risk ratio for women below age 60 and within 10 years of the onset of menopause. Non-hormonal treatment options are also available. Although a symptom driven treatment approach with individualized decision making can improve health and quality of life for midlife women, menopausal symptoms remain substantially undertreated by healthcare providers.

Identifiants

pubmed: 37553173
doi: 10.1136/bmj-2022-072612
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e072612

Commentaires et corrections

Type : ErratumIn
Type : ErratumIn

Informations de copyright

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Déclaration de conflit d'intérêts

Competing interests: We have read and understood the BMJ policy on declaration of interests and declare the following interests: none.

Auteurs

Erin R Duralde (ER)

Division of Women's Health, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA eduralde@mgb.org.
Harvard Medical School, Boston, MA, USA.

Talia H Sobel (TH)

Division of Women's Health Internal Medicine, Mayo Clinic Arizona, Scottsdale, AZ, USA.

JoAnn E Manson (JE)

Harvard Medical School, Boston, MA, USA.
Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH